Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of rare genetic disorders of obesity. The company's lead product candidate, setmelanotide, is a melanocortin-4 receptor (MC4R) agonist in development for the treatment of several rare genetic disorders of obesity, including POMC deficiency obesity, LEPR deficiency obesity, and Bardet-Biedl syndrome. Rhythm Pharmaceuticals is headquartered in Boston, Massachusetts.